Kitov Announces $10 million Registered Direct Offering
06 mai 2020 08h00 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants
20 avr. 2020 08h05 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion...
Kitov Closes $6.0 Million Public Offering
17 mars 2020 08h00 HE
|
Kitov Pharma Ltd.
TEL-AVIV, March 17, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug...
Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast
12 mars 2020 08h15 HE
|
Kitov Pharma Ltd.
Company’s marketing partners in the U.S. plan to commence selling Consensi in May 2020Kitov expects to receive between $28 million and $36 million in milestone and royalty revenues from 2020 through...
Kitov Announces Pricing of $6.0 Million Public Offering
12 mars 2020 08h00 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers
24 févr. 2020 09h00 HE
|
Kitov Pharma Ltd.
Phase 1/2 Study to Evaluate NT-219 as Monotherapy Treatment of Advanced Solid Tumors, as well as in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and...
Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results
11 févr. 2020 07h00 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24
03 févr. 2020 08h20 HE
|
Kitov Pharma Ltd.
Patent Provides Coverage Until 2035 and Strengthens Company’s IP Portfolio TEL AVIV, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage...
Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors
24 janv. 2020 08h10 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
09 janv. 2020 08h35 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...